Life Sciences

  • June 10, 2026

    Amgen Can't Amend Petition To Address Potential Double Tax

    Drugmaker Amgen isn't entitled to amend its petition to protect against possible double taxation after an eight-week trial and briefing in its income-allocation case already have been completed, the U.S. Tax Court said, noting that the trial concluded in January 2025.

  • June 10, 2026

    $25M Patent Verdict Against Ferring Backed By Del. Court

    Swiss drugmaker Ferring Pharmaceuticals Inc. on Wednesday lost its bid to dodge a $25 million verdict in a Delaware federal court patent case over an experimental enema used to treat a particularly deadly form of diarrhea.

  • June 10, 2026

    Goodwin, Covington Lead Parabilis' $670M Upsized IPO

    Venture-backed biotechnology firm Parabilis Medicines hit the public markets Wednesday after raising $670 million in its upsized initial public offering.

  • June 10, 2026

    Insurance Cos. Score Dismissal Of Zepbound Coverage Case

    A D.C. federal judge Wednesday agreed to toss a proposed class action against CVS Caremark and CareFirst BlueCross BlueShield from a worker who challenged coverage denials for Zepbound to treat sleep apnea, holding an exclusion in his employee health plan that the companies administered complied with federal benefits law.

  • June 10, 2026

    Lab To Pay $4.9M To Settle AGs' COVID Test Pricing Suit

    Eighteen states' attorneys general have entered into a $4.87 million settlement with GS Labs to resolve claims that the defunct testing company overcharged consumers for COVID-19 tests, according to statements issued Wednesday.

  • June 10, 2026

    Acadia Pharma Must Face Investors' Drug Approval Claims

    Acadia Pharmaceuticals must face investors' class action claims it misstated the likelihood that it would get regulatory approval to market its psychosis drug pimavanserin for expanded use, a California federal judge determined, finding a key question about a regulator's directions should be decided by a jury.

  • June 10, 2026

    Conn. Woman Says Pharmacy 'Grossly' Exceeded Med Dose

    A New York compounding pharmacy injured a Connecticut woman by providing her with a medication that contained a "grossly excessive" amount of the active ingredient, as much as 91,511% of the dose on the label, according to a product liability and malpractice lawsuit.

  • June 09, 2026

    Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law

    A Washington federal judge declined Tuesday to block a state law passed to protect prescription drug access for low-income and uninsured patients, rejecting arguments from AbbVie and Novartis that the new measure illegally adds to pharmaceutical manufacturers' obligations under the federal 340B Drug Pricing Program.

  • June 09, 2026

    Morrison Foerster Brings On Sidley Patent Litigation Duo

    A pair of Sidley Austin LLP patent and trade secrets litigators, including the firm's co-leader of its global intellectual property practice, have departed for Morrison Foerster LLP, according to an announcement made Tuesday.

  • June 09, 2026

    Agensys Sues Biopharmas For Alleged Trade Secret Theft

    Agensys Inc. filed a trade secret misappropriation suit in California federal court Tuesday against a U.S.-based cancer research firm and two alleged Chinese affiliates, claiming they stole confidential information for oncology antibodies developed at Agensys and that the theft was "willful and malicious."

  • June 09, 2026

    Fed. Circ. 'Recalibrates' Analysis For Constitutional Standing

    The Federal Circuit eased the line between constitutional and statutory standing last month when reviving A.L.M. Holding Co.'s infringement suit against Zydex Industries Private Ltd., in a decision attorneys say makes standing more accessible and clarifies how patent licensors can maintain their rights.

  • June 09, 2026

    4th Circ. Revives Ex-Gilead Worker's Defamation Suit

    The Fourth Circuit revived Tuesday a lawsuit from a former biopharmaceutical company employee after finding that he'd sufficiently backed his claim for vicarious liability against Gilead Sciences Inc., but refused to draw a co-worker back into the case.

  • June 09, 2026

    Eli Lilly Wins Order Halting Alleged Trulicity Fraud

    A Florida federal judge signed off Tuesday on a preliminary injunction pausing a prescription cost share program purportedly for Church of God in Christ members that pharmaceutical giant Eli Lilly and Co. says is actually a fraud scheme to resell GLP-1 drug Trulicity on the secondary market.

  • June 09, 2026

    McKesson, Rite Aid Trust Clash Over Ch. 11 Claims Transfer

    McKesson locked horns Tuesday in New Jersey bankruptcy court with a trust created by Rite Aid's first Chapter 11 plan over whether the medication supplier must hand over antitrust claims against pharmaceutical companies.

  • June 09, 2026

    BioTech Co. Hit Investor Suit Over Cancer Test Trial Miss

    Biotechnology company Grail Inc. was hit with a proposed investor class action alleging that it misled investors about the likelihood its cancer screening blood test would demonstrate effectiveness in a clinical trial, which the public learned in February was unsuccessful.

  • June 09, 2026

    Biopharma Founder's Nonsolicit Clause Void Under Calif. Law

    A biopharmaceutical company's co-founder prevailed Monday in convincing North Carolina's business court that nonsolicitation restrictions in his contract were void after they were deemed unenforceable under California law.

  • June 09, 2026

    Ex-Zydus Unit Exec Alleges 'Second-Class Citizen' Treatment

    A female executive at Zydus Pharmaceuticals' pet health unit said in New Jersey federal court that she was treated as a second-class citizen by her male counterparts, claiming she was constructively discharged due to the hostile and discriminatory conduct she faced because she is a woman.

  • June 09, 2026

    Novanta Buys Riverpoint In $1.45B Deal Steered By 3 Firms

    Medical technology provider Novanta Inc., advised by Ropes & Gray LLP and King & Spalding LLP, on Tuesday announced plans to acquire medical device maker Riverpoint Medical, led by Goodwin Procter LLP, from private equity shop Arlington Capital Partners in a deal worth up to $1.45 billion.

  • June 09, 2026

    4th Circ. Lets Hartford Unit Off The Hook For Drug Test Fight

    A Hartford unit doesn't owe coverage to a drug testing company accused of reporting false positive drug tests due to substandard quality control, the Fourth Circuit ruled Tuesday, saying the suit is related to an earlier claim that was covered by another insurer.

  • June 09, 2026

    The Law360 400: A Look At The Top 100 Firms

    The race to build the legal industry's largest law firm accelerated in 2025, with major firms leaning on mergers, lateral hiring and strategic expansion to climb the ranks of the Law360 400.

  • June 09, 2026

    Davis Polk, Slaughter & May Steer GSK's $10.6B Nuvalent Deal

    Pharma giant GSK PLC said Tuesday that it has agreed to acquire cancer therapy specialist Nuvalent Inc. for $10.6 billion as it seeks to accelerate its "rapid expansion" into the oncology market.

  • June 08, 2026

    Fed. Circ. Scrutinizes UT's 'Inflammatory' Comments In IP Trial

    The "inflammatory" language used by the University of Texas to secure a $42 million patent infringement verdict against Boston Scientific is "about as good an example as one can possibly think of," U.S. Circuit Judge Richard G. Taranto told the university's attorney on Monday.

  • June 08, 2026

    Eli Lilly Conspiracy Claim In Compound Drug Row Challenged

    A California federal court should toss part of Eli Lilly's third attempt at allegations that a telehealth company, provider group and a now-shuttered pharmacy conspired to falsely advertise compounded versions of its weight loss drugs, the companies argued in a recent motion.

  • June 08, 2026

    AIPLA, NAM Rally Behind Moderna's Fight Over Vax Patents

    The American Intellectual Property Law Association, National Association of Manufacturers and others urged the Federal Circuit to undo a lower court's ruling that Moderna, and not the government, must face a multibillion-dollar patent infringement suit over its COVID-19 vaccine.

  • June 08, 2026

    Fed. Circ. Panel Backs Invalidation Of OxyContin Patent

    The Federal Circuit on Monday upheld a Delaware federal court's decision that deemed invalid a Purdue Pharma patent covering an abuse-deterrent version of the opioid OxyContin, rebuffing the company's arguments that the lower court got its obviousness analysis wrong.

Expert Analysis

  • 4 Quick Emotional Resets For Lawyers With Conflict Fatigue

    Author Photo

    Though the emotional wear and tear of legal work can trap attorneys in conflict fatigue — leaving them unable to shake off tense interactions or return to a calm baseline — simple therapeutic techniques for resetting the nervous system can help break the cycle, says Chantel Cohen at CWC Coaching & Therapy.

  • Rescheduling Cannabis Marks New Tax Era For Operators

    Author Photo

    As the attorney general takes steps to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, operators and advisers should prepare by considering the significant changes this will bring from tax, state, industry and market perspectives, says Michael Harlow at CohnReznick.

  • Navigating Trade Secret Exceptions In Noncompete Bans

    Author Photo

    Recent and ongoing developments in the noncompete landscape, including a potential decision from the Tenth Circuit in Edwards Lifesciences v. Thompson, could offer tools for employers to bring noncompete agreements within trade secret exceptions amid an era of heightened employee mobility, say attorneys at Sullivan & Cromwell.

  • Series

    Playing Tennis Makes Me A Better Lawyer

    Author Photo

    An instinct to turn pain into purpose meant frequent trips to the tennis court, where learning to move ahead one point at a time was a lesson that also applied to the steep learning curve of patent prosecution law, says Daniel Henry at Marshall Gerstein.

  • Expect Major Shifts In Patent And Trademark Policy This Year

    Author Photo

    New leadership and initiatives promise to bring consequential changes to the U.S. Patent and Trademark Office's practices in 2026, likely favoring patent allowance and issuance, as well as streamlining trademark processes, say attorneys at Knobbe Martens.

  • Class Actions At The Circuit Courts: January Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five rulings from October and November, and identifies practice tips from cases involving consumer fraud, oil and gas leases, toxic torts, and wage and hour issues.

  • Series

    Judges On AI: How Judicial Use Informs Guardrails

    Author Photo

    U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.

  • What US Cos. Must Know To Comply With Italy's AI Law

    Author Photo

    Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.

  • Ag Bill Wording Presents Existential Threat To Hemp Industry

    Author Photo

    A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.